Will FDA’s New LDT Rule Slow Drug Development? with Dr. Mark Arnold
Episode 27
In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients. Chapters 00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360 03:45 Samaritan's Purse Charity and Community Impact 05:16 Most impactful talk at AAPS? 11:50 Comparative Analysis of FDA and EU Regulations 17:37 The Drive Behind Bioanalytical Work 22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis Takeaways The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials. Community support through charities like Samaritan's Purse is crucial during crises. The importance of collaboration in advancing drug development and bioanalytical methods. Innovations in RNA editing present new bioanalytical challenges. The drive to help patients is a key motivator for professionals in the field.
Publisher
BioTalk Unzipped
Link
biotalk-unzipped.captivate.fm/episode/fda-ldt-rule-drug-development-mark-arnold
Published
December 30, 2024
Duration
30 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Gregory Austin
BioTalk Unzipped
@biotalkunzipped
#fdas #ldtruleslow #markarnold #lifesciences #medicine
